Smith Jason Drew's Form 4 filing
UroGen Pharma Ltd. (URGN) · filed Jul 30, 2025
- Accession no.
- 0001437749-25-023963
- Filed
- Jul 30, 2025
- Trade date
- Jul 28, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions. Open-market sales total $144.0K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Smith Jason DrewCIK 0001821479 | Officer (General Counsel) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jul 28, 2025 | Ordinary Shares | MOption exerciseAcquired | +16,500 | –F2 | – | 49,014 | Direct | |
| Jul 28, 2025 | Ordinary Shares | SSaleDisposed | −7,522 | $19.14 | −$143,971.08 | 41,492 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Each performance stock unit represents a contingent right to receive one ordinary share of the Issuer.
Referenced by the price of 1 transaction in Table I.